Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
elvn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Enliven Therapeutics, Inc. (ELVN) measures how much investors pay for each dollar of the company's trailing earnings. ELVN's current PE ratio of N/A is calculated by dividing its stock price of $33.63 by its TTM earnings per share of -$1.57.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Enliven Therapeutics, Inc.You ELVN | $2.0B | N/A | — | -$1.57 |
 Atai Beckley Inc. ATAI | $1.4B | N/A | — | -$2.91 |
 Dianthus Therapeutics, Inc. DNTH | $3.4B | N/A | — | -$4.30 |
 Immatics N.V. IMTX | $1.2B | N/A | — | -$1.61 |
 Inhibrx Biosciences, Inc. INBX | $1.3B | N/A | — | -$9.04 |
 Nektar Therapeutics NKTR | $1.1B | N/A | — | -$9.73 |
 ORIC Pharmaceuticals, Inc. ORIC | $779M | N/A | — | -$1.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.83 | — | |
2024-12-31 FY2024 | — | $-1.89 | — | |
2023-12-31 FY2023 | — | $-2.01 | — | |
2022-12-31 FY2022 | — | $-6.03 | — | |
2021-12-31 FY2021 | — | $-3.17 | — | |
2020-12-31 FY2020 | — | $-4.32 | — | |
2019-12-31 FY2019 | — | $-5.43 | — | |
2018-12-31 FY2018 | — | $-2.62 | — | |
2017-12-31 FY2017 | — | $0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Enliven Therapeutics, Inc. (ELVN) measures how much investors pay for each dollar of the company's trailing earnings. ELVN's current PE ratio of N/A is calculated by dividing its stock price of $33.63 by its TTM earnings per share of -$1.57.
Frequently asked questions
ELVN pe ratio · 6 questionsELVN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $33.63 and TTM EPS of -$1.57. Data sourced from Financial Modeling Prep via ELVN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Enliven Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08